← All drugs
Drug · FAERS side-effect profile with label screen

Paroxetine Hydrochloride side effects: what 41,070 FDA adverse event reports show

Paroxetine Hydrochloride · 1,216 reaction terms · 394,687 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

41,070 reports · 84% serious · 5,352 with death outcome · 64% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ).

FDA label, Indications and Usage

What it is

DESCRIPTION Paroxetine tablets, USP are an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'-fluoroph.

FDA label, Description section

Boxed warning

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 4Labeled (related wording) 6Likely indication confounding 4Reporting / coding artifact 1Lab value / disease marker 1Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,176 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Self mutilation97167.4
128.8–217.5ROR 167.5 · calibrated p 3e-9 ✓
95.1 EB05 80.3 · IC025 +5.7
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Congenital aortic stenosis85164.1
124.1–216.8ROR 164.2 · calibrated p 4e-9 ✓
93.8 EB05 78.2 · IC025 +5.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Fallot's tetralogy117115.9
92.7–144.7ROR 116.0 · calibrated p 5e-8 ✓
76.2 EB05 65.3 · IC025 +5.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Persistent foetal circulation199110.3
93.1–130.6ROR 110.5 · calibrated p 6e-8 ✓
74.1 EB05 65.9 · IC025 +5.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=33 · ♀ 0% (drug 64%)no trial arm names this drug
Bicuspid aortic valve15581.7
68.0–98.2ROR 81.9 · calibrated p 6e-7 ✓
60.0 EB05 52.5 · IC025 +5.4
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Myoglobin urine present6581.3
61.3–108.0ROR 81.4 · calibrated p 8e-7 ✓
59.2 EB05 48.1 · IC025 +5.0
3/3 methods agree
Lab value / disease markerserious n=60 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Pulmonary valve stenosis20880.8
69.0–94.7ROR 81.0 · calibrated p 6e-7 ✓
59.6 EB05 53.1 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=31 · 100% clinicianno trial arm names this drug
Coarctation of the aorta20059.8
51.2–69.8ROR 59.9 · calibrated p 5e-6 ✓
47.4 EB05 42.1 · IC025 +5.2
3/3 methods agree
Not in label — unassessed100% clinicianno trial arm names this drug
Activation syndrome6956.9
43.7–74.1ROR 57.0 · calibrated p 8e-6 ✓
45.2 EB05 36.9 · IC025 +4.7
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Transposition of the great vessels14350.9
42.5–61.0ROR 51.0 · calibrated p 1e-5 ✓
41.6 EB05 36.2 · IC025 +4.9
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Patent ductus arteriosus71350.3
46.4–54.6ROR 50.7 · calibrated p 1e-5 ✓
41.4 EB05 38.9 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=96no trial arm names this drug
Hypoplastic left heart syndrome11145.7
37.3–56.0ROR 45.8 · calibrated p 3e-5 ✓
38.0 EB05 32.4 · IC025 +4.7
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Heart disease congenital55542.6
38.9–46.6ROR 42.8 · calibrated p 4e-5 ✓
36.0 EB05 33.5 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 0% (drug 64%)no trial arm names this drug
Atrial septal defect1,29942.3
39.9–44.9ROR 42.9 · calibrated p 3e-5 ✓
35.8 EB05 34.2 · IC025 +5.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 8.7no trial arm names this drug
Craniosynostosis13141.0
34.0–49.4ROR 41.0 · calibrated p 5e-5 ✓
34.7 EB05 30.0 · IC025 +4.7
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Ventricular septal defect85540.3
37.5–43.3ROR 40.7 · calibrated p 5e-5 ✓
34.4 EB05 32.5 · IC025 +5.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=137 · ♀ 32% (drug 64%)no trial arm names this drug
Electric shock12238.9
32.1–47.1ROR 38.9 · calibrated p 7e-5 ✓
33.2 EB05 28.5 · IC025 +4.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Congenital hydrocephalus7137.2
28.9–47.8ROR 37.2 · calibrated p 1e-4 ✓
31.9 EB05 26.1 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=40 · 100% clinicianno trial arm names this drug
Talipes39934.0
30.7–37.8ROR 34.2 · calibrated p 1e-4 ✓
29.7 EB05 27.3 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=59 · ♀ 0% (drug 64%)no trial arm names this drug
Cogwheel rigidity12029.7
24.6–35.9ROR 29.7 · calibrated p 3e-4 ✓
26.3 EB05 22.6 · IC025 +4.3
3/3 methods agree
Labeled adverse reaction
exact term
serious n=114no trial arm names this drug
Depersonalisation8927.2
21.8–33.9ROR 27.2 · calibrated p 5e-4 ✓
24.3 EB05 20.3 · IC025 +4.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
100% clinicianno trial arm names this drug
Agoraphobia13425.1
21.0–30.0ROR 25.1 · calibrated p 7e-4 ✓
22.6 EB05 19.6 · IC025 +4.1
3/3 methods agree
Likely indication confounding
term in indications
serious n=77no trial arm names this drug
Limb malformation7523.8
18.8–30.2ROR 23.8 · calibrated p 1e-3 ✓
21.6 EB05 17.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Drug exposure during pregnancy3,19323.6
22.7–24.4ROR 24.4 · calibrated p 8e-4 ✓
21.5 EB05 20.8 · IC025 +4.4
3/3 methods agree
Reporting / coding artifactserious PRR 2.9no trial arm names this drug
Cardiac murmur79123.1
21.5–24.9ROR 23.3 · calibrated p 1e-3 ✓
21.1 EB05 19.9 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious PRR 4.1no trial arm names this drug
Granuloma skin7422.7
17.8–28.8ROR 22.7 · calibrated p 0.001 ✓
20.6 EB05 16.9 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=71 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Cleft palate15520.1
17.1–23.7ROR 20.1 · calibrated p 0.002 ✓
18.5 EB05 16.2 · IC025 +3.9
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Arnold-chiari malformation7519.6
15.5–24.8ROR 19.6 · calibrated p 0.002 ✓
18.0 EB05 14.8 · IC025 +3.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Autism7919.2
15.3–24.2ROR 19.2 · calibrated p 0.003 ✓
17.7 EB05 14.7 · IC025 +3.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Serotonin syndrome1,45619.0
18.0–20.1ROR 19.3 · calibrated p 0.002 ✓
17.6 EB05 16.9 · IC025 +4.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 25.7 · serious PRR 20.6no trial arm names this drug
Derealisation16118.8
16.0–22.1ROR 18.8 · calibrated p 0.003 ✓
17.4 EB05 15.3 · IC025 +3.8
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=119no trial arm names this drug
Homicide13418.5
15.5–22.1ROR 18.5 · calibrated p 0.003 ✓
17.2 EB05 14.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=75 · ♀ 33% (drug 64%)no trial arm names this drug
Cleft lip and palate8117.9
14.2–22.4ROR 17.9 · calibrated p 0.004 ✓
16.6 EB05 13.7 · IC025 +3.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Anticholinergic syndrome11217.5
14.4–21.2ROR 17.5 · calibrated p 0.004 ✓
16.2 EB05 13.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=109 · ♀ 0% (drug 64%)no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality3,5617.57.3–7.7signal
Hyponatraemia9105.85.5–6.2signal
Extrapyramidal1,0905.35.0–5.6signal
Rhabdomyolysis / myopathy5733.63.3–3.9signal
Depression1,8953.53.3–3.6signal
Dependence / withdrawal1,7173.02.8–3.1signal
Fall / fracture1,6972.32.2–2.4signal
Liver injury1,2162.12.0–2.2raised
Arrhythmia / qt7582.01.9–2.1raised
Interstitial lung disease3662.01.8–2.2raised
Kidney injury1,7081.91.8–2.0raised
Seizure7021.81.7–2.0raised
Severe cutaneous reaction2621.81.6–2.0raised
Gi bleeding5621.61.4–1.7raised
Pancreatitis2421.51.4–1.7raised
Anaemia8061.41.3–1.5raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Paroxetine only as a background or rescue medication (NCT01360866, NCT01838681); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)6,1711.1
1.1–1.1ROR 1.1 · calibrated p 0.368
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Nausea6,0681.8
1.7–1.8ROR 1.8 · calibrated p 0.857
1.8 EB05 1.7 · IC025 +0.8Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.2 · serious PRR 1.6no trial arm names this drug
Dizziness5,4162.5
2.5–2.6ROR 2.6 · calibrated p 0.757
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.8no trial arm names this drug
Anxiety5,3794.4
4.3–4.6ROR 4.7 · calibrated p 0.276
4.4 EB05 4.3 · IC025 +2.1
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.3 · serious PRR 3.2no trial arm names this drug
Fatigue (tiredness)5,3741.6
1.6–1.7ROR 1.6 · calibrated p 0.736
1.6 EB05 1.6 · IC025 +0.6Likely indication confounding
term in indications
age-adj. PRR 1.3 · serious PRR 1.6no trial arm names this drug
Headache4,7611.8
1.7–1.8ROR 1.8 · calibrated p 0.836
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.8no trial arm names this drug
Depression4,3084.4
4.3–4.6ROR 4.6 · calibrated p 0.282
4.4 EB05 4.3 · IC025 +2.1
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.1 · serious PRR 3.0no trial arm names this drug
Diarrhoea (diarrhea)3,9011.4
1.4–1.5ROR 1.4 · calibrated p 0.593
1.4 EB05 1.4 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.5no trial arm names this drug
Insomnia (trouble sleeping)3,8273.4
3.3–3.5ROR 3.5 · calibrated p 0.494
3.3 EB05 3.2 · IC025 +1.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 2.9no trial arm names this drug
Vomiting3,2781.6
1.6–1.7ROR 1.6 · calibrated p 0.737
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.5no trial arm names this drug
Suicidal ideation (thoughts of suicide)3,2308.4
8.1–8.7ROR 8.7 · calibrated p 0.051
8.2 EB05 7.9 · IC025 +3.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 7.0 · serious PRR 5.3no trial arm names this drug
Drug exposure during pregnancy3,19323.6
22.7–24.4ROR 24.4 · calibrated p 8e-4 ✓
21.5 EB05 20.8 · IC025 +4.4
3/3 methods agree
Reporting / coding artifactserious PRR 2.9no trial arm names this drug
Pain3,1411.2
1.1–1.2ROR 1.2 · calibrated p 0.434
1.2 EB05 1.1 · IC025 +0.2Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.2 · serious PRR 1.1no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Paroxetine (SSRIs) ↔ Discontinuation (withdrawal) syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Paroxetine?

In FDA FAERS, the most frequently co-reported reaction terms for Paroxetine are drug withdrawal syndrome, nausea, dizziness, anxiety, fatigue, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Paroxetine have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.

Do FAERS signals prove that Paroxetine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.